bromodeoxyuridine has been researched along with l 744832 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feldkamp, MM; Guha, A; Lau, N | 1 |
1 other study(ies) available for bromodeoxyuridine and l 744832
| Article | Year |
|---|---|
Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Astrocytoma; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bromodeoxyuridine; Cell Cycle; Cell Division; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Endothelial Growth Factors; Enzyme Inhibitors; ErbB Receptors; Farnesyltranstransferase; Genes, ras; Growth Inhibitors; Humans; Lymphokines; Membrane Proteins; Methionine; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Myelin Basic Protein; Neovascularization, Pathologic; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1999 |